Nuvation Bio Inc. growth

Reported trailing growth, forward expectations and three-year compound growth rates.

Trailing growth

Year over year

Revenue: +1205.5%
EBITDA: +78.6%
EBIT: +76.2%
EPS: +81.9%
Free cash flow: +20.0%
Operating cash flow: +20.1%

Forward estimates

Revenue: -30.8%
EBITDA: +145.8%
EPS: +52.8%

Three-year CAGR

Revenue: +699.0%
EBITDA: +66.6%
EBIT: +64.0%
Net income: +64.0%
EPS: +71.6%
Free cash flow: -33.1%

Latest available reported and market-derived figures. A dash means the source dataset does not currently cover that metric; it does not imply a zero value.